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Background: Lipidomic analysis was performed to explore differences in lipid profiles between plasma from lean
and obese subjects, followed by in vitro methods to examine a role for the identified lipids in endothelial cell
pathophysiology.
Methods: Plasma was collected from 15 morbidly obese and 13 control subjects. Lipids were extracted from
plasma and analyzed using LC/MS, and MS/MS to characterize lipid profiles and identify lipids that are elevated in
obese subjects compared to lean.
Results: Orthogonal partial least squares-discriminant analysis (OPLS-DA) modelling showed that lipid profiles were
significantly different in obese subjects compared to lean. Analysis of lipids that were driving group separation in
the OPLS-DA model and that were significantly elevated in the obese group led to identification of a group of
ether-linked phosphatidylcholine (PC) and phosphatidylethanolamine (PE) lipids of interest. Treatment of human
coronary artery endothelial cells with the ether-linked phosphatidylethanolamine induced expression of cell
adhesion molecules, a hallmark of endothelial cell activation. However, oxidized phosphatidylcholine products that
can induce endothelial cell activation in vitro, were not significantly different between groups in vivo.
Conclusion: These data suggest a role for ether-linked lipids in obesity associated dyslipidemia and vascular disease.
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Dyslipidemia and oxidative stress are characteristic of
obesity and diabetes, and appear to play a major role in
diabetes, cardiovascular disease, and cancer [1,2]. Obes-
ity is associated with increased circulating lipids, and
increased oxidized LDL that leads to inflammation and
oxidative stress in vascular endothelial cells and con-
tributes to the pathophysiology of the metabolic syn-
drome and atherosclerosis [3,4]. Ectopic fat deposition
in morbidly obese individuals also contributes to the
pathogenesis of vascular and metabolic disturbances by
inhibiting insulin action and disrupting lipid metabol-
ism in the adipose, liver, pancreas, kidney and skeletal,* Correspondence: e.donovan@auckland.ac.nz
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reproduction in any medium, provided the orsmooth and cardiac muscle [5]. Phosphatidylcholine (PC)
species that contain polyunsaturated fatty acids, particu-
larly arachidonate, at the sn-2 position are especially
susceptible to free radical oxidation [6]. One such PC is 1-
palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine
(PAPC), which is a common cell membrane constituent,
and circulates within cholesterol particles. PAPC and





lysophosphatidylcholine (lyso-PC) have been shown to
induce cell adhesion molecule expression and inflam-
matory mediator secretion in endothelial cells and have
been implicated in atherosclerotic progression [7-12],
and oxidized phospholipids are found deposited in ath-
erosclerotic plaques [6,13]. Because PC is the mostal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ucts detected contain the choline head group [14].
However, other lipid classes and additional oxidized
phospholipids are likely involved in vascular pathology,
and it is likely that interactive effects between lipids
contribute to CVD/metabolic disease pathophysiology.
In addition to (oxidized) phospholipids, other lipids in-
cluding but not limited to saturated and polyunsaturated
fatty acids and ether-linked lipids have been examined in
the relation to metabolic syndrome and cardiovascular
disease. Ether-linked lipids, characterized by an ether
linkage between the glycerol backbone and one or both
fatty acid side chains (usually the sn-1 position) as op-
posed to an ester linkage, and plasmalogens, a subclass
of ether-linked lipids characterized by a vinyl ether link-
age at the sn-1 position with an ester linkage at the sn-2
position, have also been the subject of recent research.
Plasmalogens may function as free radical scavengers,
and ether-linked lipids can serve as arachidonic acid
reservoirs in cell membranes [15-17]. The role of
ether-linked lipids and plasmalogens in metabolic and
cardiovascular disease is still not well understood as
there is lack of concensus in the data as to patterns of
change in ether-linked lipid distribution with different
metabolic syndrome characteristics [18,19].
Lipidomics is broadly defined as the large-scale study
of pathways and networks of cellular lipids in biological
systems. Lipidomics can be used to examine the pres-
ence and structure of the range of lipid species within
different tissues making it an attractive method for
examining distribution of phospholipids in tissue, as well
as for globally examining differences in lipids between
subject groups. A broad examination of lipid species that
are elevated and potentially contribute to metabolic and
cardiovascular disease pathologies in morbidly obese
humans could provide insight into the link between
obesity and pathogenesis of atherosclerosis and facilitate
discovery of lipid biomarkers that increase disease risk.
The purpose of this study was to: 1) use a shotgun
lipidomics approach to examine global lipid distribution
in plasma from lean and morbidly obese humans, to
identify lipids that are elevated in the morbidly obese
population that may contribute to metabolic and cardio-
vascular pathology, 2) examine the effects of lipids iden-
tified in our shotgun analysis as elevated in obese
subjects in an in vitro endothelial cell model to deter-
mine whether they induce disease related phenotypic
changes, and 3) use a targeted lipidomics approach to
determine if there is a difference in distribution of oxi-
dized phospholipids in plasma from lean and morbidly
obese humans. We hypothesized that lipid profiles
would be significantly different in plasma from morbidly
obese humans compared to lean, and that lipids identi-
fied in our shotgun approach that are elevated in obesesubjects compared to lean would induce inflammatory
changes in endothelial cells. In addition, we hypothe-
sized that oxidized phospholipids shown previously
in vitro to cause endothelial cell production of inflam-
matory mediators and cell adhesion molecules would be
greater in plasma from obese humans compared to lean.
Materials and methods
Ethics statement
The Institutional Review Boards of Colorado State Univer-
sity and Poudre Valley Hospital approved this protocol
(CSU protocol #- 05-116H, PVH protocol #- 07–874).
Each volunteer was informed of the potential risks and
written consent was obtained prior to enrolment. The
study followed the guidelines set forth by the Declaration
of Helsinki.
Study overview
A total of 15 morbidly obese gastric bypass patients, and
13 non-obese controls age 18–60 were recruited to par-
ticipate through the Northern Colorado Surgical Associ-
ates (NCSA) of the Bariatric Center of the Rockies.
Bypass patients were required to have a body mass index
(BMI) > 40 kg/m2, while controls were required to have
a BMI < 30 kg/m2. There were no other exclusion cri-
teria allowing the subject population to be heteroge-
neous and, thus, differences in lipid profiles between
groups are representative of the general clinical popula-
tion. Subjects completed medical and exercise question-
naires prior to undergoing a venipuncture blood draw
following a 12-hour fast. Blood was collected in vacutainer
tubes containing EDTA, 0.5 mL were aliquoted for
HbA1C analysis, and the remainder was centrifuged
(1200 g, 15 min, 4°C) for collection of plasma which was
stored at −80°C until lipid extractions were performed.
Subject characteristics
Participant characteristics are shown in Table 1. We
were unable to obtain body composition data because
subject size exceeded the capacity of the available dual
energy x-ray absorptiometry (DEXA) equipment. Height
and weight were measured at the surgical center, while
other demographic and health information was obtained
through a health history questionnaire. None of the sub-
jects were undergoing active weight reduction prior to
surgery. Whole blood samples were sent to the Univer-
sity of Colorado Denver Clinical Translational Research
Center for analysis of hemoglobin A1C (HbA1C) using a
DCA Vantage analyzer (Siemens, Deerfield, IL).
Lipid extraction
Lipid extractions were performed using the methyl-tert
butyl ether (MTBE) method described by Matyash et al.
[20], with all steps performed in the Captair Pyramid
Table 1 Subject characteristics
Control Obese
n = 13 n = 15
(F = 11, M = 2) (F = 10, M = 5)
Age (yr) 42 44
Height (in) 65 ± 3 67 ± 3
Weight (kg) 71 ± 14 142 ± 33 *
BMI (kg/m2) 25.76 ± 4.39 49.87 ± 11.27 *
BMI min 20 41
BMI max 31 87
HbA1C (% of total) 5.15 ± 0.10 6.41 ± 0.35 *
Current smokers 2 1




Anti-anxiety and anti-depressants 4 5
* = p < 0.01 compared to control. Data are presented as Mean ± SE.
Donovan et al. Diabetology & Metabolic Syndrome 2013, 5:24 Page 3 of 13
http://www.dmsjournal.com/content/5/1/24glove box (Erlab, Rowley, MA) under argon gas to pre-
vent exposure to oxygen and subsequent oxidation of
lipids. Briefly, 200 μL plasma was added to 80 μL of MS
grade H2O in a glass tube with a Teflon lined cap,
followed by addition of 1.5 mL of molecular grade
methanol. The tubes were vortexed, 5 ml of molecular
grade MTBE was added, and then the samples were
rocked for 1 hr at room temperature. Following the in-
cubation, 1.25 mL of MS grade H2O was added and the
tubes were vortexed and centrifuged at 1,000 × g for
10 min. The upper organic phase was collected, placed
in another glass tube with a Teflon lined cap, and dried
under nitrogen gas. Samples were re-suspended in 1 mL
of LC-MS grade methanol and topped with high purity
argon gas. Samples were stored for no longer than one
week at −20°C prior to chromatographic analysis. Sam-
ples were put in random order prior to lipid extraction,
and again prior to mass spec analysis.
Liquid chromatography/mass spectroscopy (LC/MS)
Both the targeted and shotgun analysis were performed
on lipid extracts, with lipids separated by reversed phase
ultra performance liquid chromatography (UPLC) on an
Acquity instrument (Waters, Milford MA). Solvent A
consisted of an 89:5:5:1 mixture of water, isopropyl alco-
hol, acetonitrile and 500 mM ammonium acetate re-
spectively. Solvent B consisted of a 50:49:1 mixture of
isopropyl alcohol, acetonitrile, and 500 mM ammonium
acetate, respectively. All solvents were LC-MS grade
(Fisher, Optima LCMS). One microliter injections were
loaded to a 1.0 × 100 mm Acquity BEH C8 column heldat 50°C with a 140 μL/min flow of 100% solvent A. Solv-
ent A was held at 100% for 0.1 min, followed by a linear
gradient to 40% Solvent A over 0.9 min. A second linear
gradient to 100% Solvent B was achieved over 10 mi-
nutes, followed by a 3 min hold at 100% Solvent B. The
chromatographic system was returned to initial condi-
tions via a 0.1 min linear gradient to 100% Solvent A,
followed by a 5.9 min equilibration prior to the subse-
quent injection. Total run time was 20 min. Eluate
was introduced to a Q-ToF Micromass spectrometer
(Waters/Micromass, Manchester, UK) via electrospray in
either the positive or negative ionization mode. Capillary
voltages were held at 3000 V and 2200 V in positive and
negative ionization modes, respectively. In both modes
the sample cone voltage was held at 30 V, the collision
energy was held at 7 V, the source temperature was held
at 130°C, and the desolvation temperature was held at
300°C. Data was acquired over the 100–1200 m/z range
in all analyses, at a rate of 2 scans/sec. The sample set
was analyzed in independently randomized technical du-
plicate for each ionization mode. Both the UPLC and
mass spectrometer were operated using MassLynx soft-
ware version 4.1 (Waters, Milford, MA).
Peak detection and integration were performed using
MarkerLynx software (Waters, Milford MA). Chromato-
graphic peaks eluting between 0 and 14 min with m/z
values between 100 and 1200 were detected using a
mass window of 0.07 Daltons and a retention time win-
dow of 0.1 min. Apex Track peak parameter settings
were used, with peak width and baseline noise set for
automatic calculation. A threshold of 10 counts/scan, a
noise elimination level of 6 was implemented to minimize
the detection of spectral noise, and the deisotope option
was enabled to exclude isotopic peaks from the final data
matrix of detected features and their intensities across all
samples.
OPLS modelling
For the shotgun analysis, multivariate statistical analysis
was performed using SIMCA-P+ software (Umetrics
Kinnelton, NJ). We used principal components analysis
(PCA), and combined PLS and orthogonal single correc-
tion discriminant analysis (OPLS-DA) to analyze the
LC/MS data. In short, PCA is an unbiased analysis of
the total metabolite content (in our analysis the total
plasma lipid profile) that detects variance among sam-
ples and provides sample clusters based on similarity
of molecular profile. OPLS-DA is an extended form of
partial least squares-discriminant analysis (PLS-DA)
that, in addition to explaining overall differences be-
tween classes, separates predictive and non-predictive
variation [21]. Data were modelled to visualize dis-
crimination between the obese and control groups
using the OPLS-DA model and scores plot of the first
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fied by R2X and R2Y, and predictability by Q2Y.
Lipid ion analysis
A strict analysis and reduction to specific lipid ions of
interest was performed using the models and scores plots
from the OPLS-DA analysis, along with the raw LC/MS
data. Factors in addition to obesity, including medication
use in the control population, could influence and poten-
tially weaken our model because of the heterogeneity of
the subject population. However, lipids that emerge as sig-
nificantly different between non-obese and obese despite
the potential weakness of group heterogeneity, best repre-
sent the differences due to obesity in the general clinical
population. First, a list was compiled of all the ions falling
between 0.5 and 1 on the scores plots from both positive
and negative mode because these ions were driving the
difference between groups in the OPLS-DA model. An
additional list was compiled containing all ions that were
significantly different between groups based on t-tests
comparing feature abundance between groups. All ions on
the t-test list with a difference of less than 2 fold between
obese and control groups were excluded, as were the fea-
tures with abundances too low to be distinguished as an
actual lipid ion, allowing us to narrow the list to approxi-
mately the most significantly different 10% of the ions.
The remaining ion features on the t-test list were cross-
referenced with the ion features on the scores plot list. A
final list was compiled of ion features that were present on
the scores plot list and final t-test list. These were the lipid
ions that were both driving the difference between groups
observed in the OPLS modelling, and that were statisti-
cally significantly different between groups. Ions on this
list were further examined using tandem mass spectros-
copy (MS/MS).
Tandem mass spectroscopy and lipid identification
Samples were analyzed by MS/MS as described above
for the initial LC/MS analysis with the exception of se-
lective mass filtering with the quadrupole for our ions of
interest, and a collision energy of 40 V. Fragmentation
patterns were analyzed and cross referenced to Lipid
Maps mass spectrometry peak prediction resources
[22], and matched with published spectra where avail-
able for identification of lipids of interest. Standards
were commercially available (Avanti Polar Lipids,
Alabaster, AL) for three of the tentatively identified




(1’-myo-inositol))and we performed MS/MS on those
available to confirm our tentative identifications. Following
confirmation of our tentative identifications, we used theether-linked phosphoethanolamine standard in cell culture
treatments to determine if it induced pathological pheno-
typic changes in endothelial cells.
Cell culture and lipid treatments
Primary human coronary artery endothelial cells (HCAEC)
(Lonza, Walkersville, MD) were grown in endothelial cell
growth medium (EBM-2) containing 5% FBS and manufac-
turer recommended supplemental growth factors, antibi-
otics, and antimycotics. All assays were performed on cells
at 80-100% confluence, between passages 3 and 9. Lipid
treatments included normal medium, vehicle controls,
and the 1-0-1’-(Z)-Octadecenyl-2-Arachidonoyl-sn-Glycero-
3-Phosphoethanolamine (PE) standard. This PE standard
was used for endothelial cell treatments as a representative
ether-linked lipid because it was the ether-linked standard
on our list that was commercially available. Treatment con-
centration for the PE standard was 25 μg/mL, with all treat-
ments performed for 4 hrs and repeated a minimum of
three times in duplicate or triplicate. HCAEC were also
treated with L-α-Phosphatidylcholine (PC) standard (Avanti
Polar Lipids, Alabaster, AL), and PC standard that was oxi-
dized by exposure to room air for 48 hrs as previously de-
scribed [13], to confirm the effects of previously described
oxidized PAPC in our model.
Western blot analyses
HCAEC were seeded in 65 mm polystyrene cell culture
dishes and grown to at least 80% confluence prior to lipid
treatment. Following treatment, cells were scraped in RIPA
buffer (50 mM Tris, 0.15 M NaCl, 1% Na deoxycholic acid,
1 mM EGTA, 1% NP40) containing protease and phos-
phatase inhibitors, and sonicated 3 × 10 sec. Protein con-
centrations were determined using a BCA assay, and
samples were diluted with the appropriate volume of
Laemmli sample buffer for loading 25 μg protein per well.
Samples were separated on 7.5% polyacrylamide gels at
125 V, and transferred to nitrocellulose membranes
(BioRad, Hercules, CA) for 1 hr at 50 V. Membranes were
blocked for 1 hr in Superblock (Thermo Scientific,
Rockford, IL) and then incubated with primary antibodies
against VCAM (1:200) and ICAM (1:200) followed by the
appropriate HRP-conjugated secondary antibodies. Mem-
branes were developed by chemiluminescence using
SuperSignal West Dura substrate (Thermo Scientific,
Rockford, IL), with digital images obtained using the
Biospectrum UVP system (Upland, CA). All signals
were normalized to β-actin obtained from the same
blot, and expressed as the percent of the normal
medium control condition.
ELISA analysis
Monocyte chemoattractant protein-1 (MCP-1) in the
cell culture medium was determined using a sandwich
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performed according to manufacturer instructions. The
lower limit of detection was 31.2 pg/mL and average CV
was 2.2%.
Statistical analysis
Modelling and analysis of LC/MS data are described
above. Comparison of ion abundance between obese and
control groups, and lipid treatment effects on HCAEC
were performed using unpaired t-tests. Significance was
set a priori at p ≤ 0.05.
Results
Subject characteristics
There was no difference in average age between groups,
but average BMI was significantly higher (p < 0.01) in the
morbidly obese group (49.87 ± 11.27 kg/m2) compared to
control (25.76 ± 4.39 kg/m2) and HbA1C was significantlyFigure 1 Principle components analysis models for all ions for all subhigher (p < 0.01) in the morbidly obese group (6.41 ±
0.35% of total) compared to control (5.15 ± 0.10% of total)
(Table 1).
Global lipidomic analysis
For both the shotgun and targeted analysis we analysed
lipid extracts from control and obese subjects using
LC/MS. We then began the analysis for the shotgun
approach with the principle component analysis (PCA).
PCA models (Figure 1) for positive and negative mode
poorly classified the control and obese groups, which was
not unexpected given the heterogeneity of the groups. The
PCA model eliminated outliers prior to the biased OPLS-
DA analysis. OPLS-DA modelling was performed on the
remaining control and obese lipid profile data obtained in
both positive and negative mode. The positive mode model
and a representative scores plot are shown in Figure 2A,
the negative mode model and a representative scores plotjects detected in positive and negative mode.
A. B.
Figure 2 OPLS-DA models and representative scores plots from positive mode analysis (A) and negative mode analysis (B). Black
markers in the OPLS model represent lean controls, red markers represent obese pre-operative subjects. Each triangle on the scores plot
represents an ion that was detected. The red boxes show the ions that were screened for further analysis.
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mode model were 0.298, 0.839, and 0.259 respectively,
while R2X, R2Y, and Q2Y of the negative mode model were
0.49, 0.658, and 0.216 respectively. Our values are similar
to analyses in other heterogeneous diseased human popu-
lations [23]. Based on the OPLS-DA models and statistical
analysis as described above, a list of 43 lipid ions of interest
that were significantly different between groups and driving
the group separation in the OPLS-DA model was compiled
for further examination (Additional file 1: Table S1), 26 of
those were greater in obese subjects.
Lipid ion of interest identification
MS/MS analysis was performed on all lipid ions of inter-
est. Following MS/MS analysis, screening of spectra,
comparison of fragments in Lipid Maps, comparison to
published spectra, and elimination of ions that were un-
identifiable or became negligible, 22 ions of interest were
tentatively identified. Numerous tentatively identified
ions were present as multiple adducts, Table 2 shows
the final list of ions of interest that were greater in
obese subjects and of interest for further study. Wediscovered that multiple ether-linked phospholipids were
significantly higher in the obese group compared to con-
trol and were driving group separation in the OPLS-DA
model.
To confirm our tentative ion identifications, where
available we compared previously published spectra of
our tentatively identified ions to our spectra. Figure 3
shows a representative MS/MS spectra of PE(P-18:0/20:4
(5Z,8Z,11Z,14Z)) an ether-linked phosphatidylethanol-
amine (PE), in one of our samples, that was identified in
negative mode, and a previously published spectra of the
same ion confirming our tentative identification of that
ion. Published spectra for this PE can also be found in
Goodenowe et al. showing the same fragmentation pat-
tern [24]. We also purchased the standards that were
available from our list to analyze via MS/MS and com-
pared the spectra of our unknown ions to the spectra of
the standards. Spectra from the standards that were
analysed matched the spectra of our unknowns confirming
the identity of those ions. Figure 4 shows the chromatog-
raphy and MS/MS spectra of PI(18:0/20:4(5Z,8Z,11Z,14Z))
from the purchased standard (top chromatogram and
Figure 3 Representative spectrogram of the ion m/z 750.5399 from MS/MS analysis that was identified as the plasmalogen
phosphatidylethanolamine PE(P-18:0/20:4(5Z,8Z,11Z,14Z)), along with a previously published MS/MS spectrogram of the same species.
Peak patterns match with the exception of a fragment of 331 in the previously published spectra resulting from presence of a minor
additional isomer.
Table 2 Identifications of ions from MS/MS analysis
Ion of interest from
original LC/MS analysis
Tentative ID based on MS/MS analysis P-value Ave (c) Ave (pre)
750.5399 PE(P-18:0/20:4(5Z,8Z,11Z,14Z)) 0.016 8.25 13.73
838.5599 PE(18:2(9Z,12Z)/20:2(11Z,14Z)) 0.039 17.67 27.82
829.57 PC(16:0/18:2(9Z,12Z)) 0.022 0.01 0.18
802.5599 PC(O-16:0/18:2(9Z,12Z)) 0.019 49.22 64.29
816.57 PC(O-16:0/18:2(9Z,12Z)) 0.031 161.81 208.10
830.59 PC(O-18:0/18:2(9Z,12Z)) 0.003 32.48 45.40
844.5999 PC(O-18:0/18:2(9Z,12Z)) 0.005 94.68 130.23
832.5999 PC(O-18:0/18:1(9Z)) 0.005 8.85 14.46
868.5999 PC(O-18:0/20:4(5Z,8Z,11Z,14Z)) 0.010 41.54 63.87
870.6199 PC(O-18:0/20:3(8Z,11Z,14Z)) 0.028 30.86 44.71
885.5499 PI(18:0/20:4(5Z,8Z,11Z,14Z)) 0.011 45.66 62.11
p-values were calculated using an unpaired t-test comparison of group relative abundance means for each ion from the original run. c = control, pre = obese
pre-surgical. Ave (c) and (pre) values are average relative abundance in arbitrary units of each ion for each group from the original run.
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Figure 4 Chromatography and MS/MS spectra of ion m/z 885.5499 (PI(18:0/20:4(5Z,8Z,11Z,14Z)) from the purchased standard (top
chromatogram and spectra) and a sample (bottom chromatogram and spectra). Fragmentation patterns match at major peaks 885- parent
ion, 581- parent ion with loss of sn-2 arachidonic acid side chain m/z 303, 303- liberated arachidonic acid, 283- liberated stearic acid, and 241-
inositol head group.
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tra). Retention times match, and major identifying peaks
include 885 (parent ion) 303 (20–4 arachidonic acid) 283
(18–0 steric acid), and 241 (inositol head group). Because
the exceptional finding from the shotgun analysis was the
emergence of the group of ether-linked lipids, we next
sought to examine what potential effects ether-linked lipids
may have on endothelial cells, to obtain insight into the re-
lationship between obesity associated dyslipidemia and vas-
cular disease.
Endothelial cell response to ether-linked
phosphatidylethanolamine and oxidized PAPC
To determine the effect of our identified ether linked
lipids on endothelial cells, we used PE-(P-18:0/20:4(5Z,8Z,11Z,14Z)) (p-PE), the only commercially available
ether-linked lipid on our final list, to treat HCAEC. p-PE
induced increases in the cell adhesions molecules ICAM
(158% of control, p = 0.028) and VCAM (144% of con-
trol, p = 0.038) (Figure 5). Cell culture medium was col-
lected for analysis of the secreted inflammatory mediator
MCP-1. MCP-1 did not differ in medium collected from
cells incubated in normal medium, and those that were
exposed to p-PE (Figure 6). Because previous studies
have described induction of ICAM and VCAM by oxi-
dized phospholipids, we also used oxidized phosphatidyl-
choline (ox-PC) to treat HCAEC. Ox-PC also induced
increases in ICAM (180% of control, p = 0.038) and
VCAM (169% of control, p = 0.051), while there was no
effect of un-oxidized PC.
Figure 5 Effects of lipid treatment on HCAEC cell adhesion molecule protein expression. pPE increased ICAM protein (158% of control,
p = 0.028) and VCAM protein (144% of control, p = 0.038) in HCAEC. Data are presented as Mean ± SE.
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Because previous in vitro data indicate that ox-PC prod-
ucts cause pathological phenotypic changes in endothe-
lial cells, we targeted PC and ox-PC in our LC/MS data
from morbidly obese and control plasma using a
targeted approach. We scanned all ions in the positive
mode analysis for any that could be PC, PGPC, POVPC,
or PEIPC based on m/z and abundance. While none of
the best potential matches for these lipids were between
0.5 and 1 in our OPLS-DA models, one potential PC







Figure 6 Effects of lipid treatment on HCAEC MCP-1 secretion.
No differences were detected between treatments. Data are
presented as Mean ± SE.subjects compared to control (p = 0.040), though the
other potential match had a much higher relative abun-
dance (as would be expected for PC because it is the
most abundant phospholipid in cells) and was not sig-
nificantly different. Of the best matches for the ox-PC
species, only those for PGPC were close to significantly
elevated in the obese compared to control (p = 0.052,
and 0.055), while the best potential matches for PEIPC
were not significant (p = 0.707, and 0.661) and no ions
that could represent POVPC were detected (Table 3).Discussion
Lipidomics often functions as a hypothesis generating
technique where biomarkers of interest emerge from
large data sets indicating further analysis of physiological
roles of identified features. Because obesity is a major in-
dependent risk factor for coronary artery disease, and a
major component of that risk is dyslipidemia, we sought
to characterize the lipid profiles from morbidly obese
human subjects compared to control. We combined
in vivo and in vitro methods to examine the effects of
lipids that were identified and elevated in obese subjects
on pathophysiology of endothelial cells. The major find-
ings of this study were that a group of ether-linked lipids
was elevated in plasma from morbidly obese subjects com-
pared to control, and PE-(P-18:0/20:4(5Z,8Z,11Z,14Z)) in-
creased cell adhesion molecule protein but not the
inflammatory mediator MCP-1 in endothelial cells. In
addition, PAPC, PGPC, POVPC, and PEIPC were not ele-
vated in our obese group compared to control.
Table 3 Oxidized PAPC products from positive mode analysis
Phospholipid Expected m/z Best match P-value Ave (c) Ave (pre) Scores plot location
PAPC 782.7 11.10_782.6904 0.04 0.029 0.11 x = 0.005 y = 0.4
8.43_782.5644 0.49 289.14 269.649 x = −0.04 y = −0.1
PGPC 610.2 9.53_610.1888 0.052 0.066 0.262 x = 0.01 y = 0.4
9.40_610.1828 0.055 15.347 26.288 x = 0.1 y = 0.53
POVPC 594.3 No ions detected at this mass
PEIPC 828.6 8.31_828.5536 0.707 3.269 3.06 x = 0 y = 0
8.32_828.6107 0.661 0.191 0.157 x = 0 y = 0
p-values were calculated using an unpaired t-test comparison of group means for each ion. c = control, pre = obese pre-surgical. Ave (c) and (pre) values are
average relative abundance in arbitrary units of each ion for each group. Scores plot locations represent the coordinates of the location of each ion on the
positive mode scores plot shown in Figure 3.
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There was a significant difference in the lipid profiles be-
tween our control and obese subjects. Following our con-
servative and strict approach to narrowing down the total
lipid profile to a small list of lipids of interest, a group of
ether-linked phospholipids that were elevated in obese sub-
ject plasma compared to control that were driving the sep-
aration of groups in our model emerged. Ether-linked lipids
are characterized by an ether linkage as opposed to an ester
linkage at one or both fatty acid side chains, with the sub-
class plasmalogens having a vinyl ether linkage. Standard
ether-linked lipids as well as plasmalogens both appeared
on our list, and the ether-linked phosphatidylethanolamine
used in our in vitro experiments was a plasmalogen.
Ether-linked lipids have been characterized in macro-
phages, lens cells, adipose, liver, and serum [25-27]. In
the context of metabolic disease, reports detailing ether-
linked lipid presence and alteration vary. A recent
lipidomic analysis on serum, liver, subcutaneous adipose,
and intraabdominal adipose from a group of obese sub-
jects was showed that ether-linked PEs were higher in
liver compared to both adipose depots, but ether-linked
PCs were higher in adipose depots [26]. In this analysis
ester PCs were more abundant in all tissues compared
to ether-linked, but ether-linked PEs were more abun-
dant than esters in all tissues. Graesssler et al. found a
significant increase in multiple PE plasmalogens in indi-
viduals with BMI > 27.5, but diminished ether-linked
lipids in individuals with increasing HOMA-IR [19].
A comparison of obese and non-obese twins found
that more ether-linked phospholipids were dimin-
ished in the obese twin compared to the lean than
were elevated [28]. Other recent work profiling lipid
composition of LDL found that plasmalogen PEs are
decreased in metabolic syndrome patients compared
to lean, as well as in diabetics compared to lean, and
the proportion of plasmalogen PE negatively corre-
lates with waist circumference [29]. Conversely, it has
also been reported that plasmalogen presence isgreater in hypercholesterolemic subjects [30], and
that the ratio of plasmalogen PE to ester PE was in-
creased in a population of diabetic patients without
cardiovascular complications compared to controls
[31]. In the present study we did not have enough
subjects to stratify results based on diabetes in our
obese group. Collectively, the work of others as well
as the current investigation support further examin-
ation of why ether-linked phospholipids vary between
lean control and obese subjects and what the role of
ether-linked lipids in metabolic disease may be. It
may be that the effects and presence of individual
ether-linked and plasmalogen PCs and PEs varies de-
pending on individual disease severity and milieu.
Physiological roles of ether-linked lipids
Ether-linked phospholipids are present in most cell
membranes and studies of their function have ranged
from signalling in brain cells to antioxidant properties
[32-35]. There is a lack of consensus about whether
ether-linked lipids are pro-or anti-oxidant and inflam-
matory. Ether-linked lipids, such as those identified in
the current study, are more susceptible to oxidation
compared to ester-linked lipids [34,35]. Ether-linked
plasmalogens in particular are preferentially oxidized
over ester-linked phospholipids, possibly due to struc-
tural differences leaving the polyunsaturated sn-2 side
chains more exposed [36], and lower bond dissociation
energies of ether linkages [33]. Decreased plasmalogens
in LDL from patients with the metabolic syndrome and
diabetes has been suggested as an indicator of oxidative
stress [29]. In the current study it may be that the ob-
served ether-linked lipids are elevated as an antioxidant
response to increasing oxidative stress with obesity, and
as noted earlier reports vary in regard to increases and
decreases in ether-linked lipids based on various symp-
toms of the metabolic syndrome. Whether ether-linked
lipids function as ROS scavengers or are simply more
susceptible to oxidation remains to be seen. However if
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synthesized in response to a pro-oxidant environment or
altered membrane fluidity, this may be of interest in ref-
erence to obese and diabetic populations where in-
creased oxidative stress is often a problem.
Ether-linked lipids may be pro-inflammatory and
can serve as arachidonic acid reservoirs. Ether-linked
lipids, particularly plasmalogens have a high propor-
tion of arachidonic acid at the sn-2 position, and are
involved in membrane remodeling as well as intracel-
lular arachidonic acid metabolism [15,16]. Arachi-
donic acid released from the sn-2 position of ether
and ester lipids can be enzymatically oxidized to form
prostaglandins, prostacyclin, thromboxanes, and leu-
kotrienes, all of which are pro-inflammatory [37,38].
Ether-linked lipids and oxidation products of ether-linked
lipids include proinflammatory lysophospholipids that
are platelet activating factor (PAF) precursors, and
lysophospholipids independently can be pro-inflammatory
and pathological. Lysophosphocholines (LPCs) have been
shown to increase plasminogen activator inhibitor-1, a po-
tent prothrombotic and proatherogenic protein [39]. In
addition, LPCs can induce endothelial cell expression of
cell adhesion molecules, an important step in endothelial
cell activation and atherosclerotic progression [40,41].
Ether-linked lipids with arachidonic acid at the sn-2
position serve as PAF synthesis precursors. PAF is an
ether-linked species with a choline head group, an ether-
linked fatty acid at the sn-1 position and an acetyl group
at the sn-2 position that is a potent stimulator of the
platelet coagulation cascade, thrombosis, and inflamma-
tion. PAF has been implicated in atherogenesis because
it activates and recruits inflammatory cells, and in ad-
vanced plaque rupture because it initiates the coagula-
tion cascade in platelets (reviewed in [42]). What is
unknown is whether PAF formation only occurs in re-
sponse to external stimuli, or if formation of PAF can be
driven by excess substrate availability. The ether-linked
phospholipids, including those identified in our analysis
with arachidonic acid at the sn-2 position and choline
head groups, may serve as substrate for PAF formation
and thus be characterized as pro-inflammatory.Ether-linked phospholipids and HCAEC
To address whether ether-linked lipids can induce
phenotypic changes in endothelial cells, we performed
in vitro experiments using a commercially available
ether-linked PE, PE-(P-18:0/20:4(5Z,8Z,11Z,14Z)), that
corresponded to a species we identified as elevated in
obese subjects. This PE stimulated cell adhesion mol-
ecule expression in human coronary artery endothelial
cells a key step in atherogenesis. The increases we ob-
served in cell adhesion molecule expression were similarin magnitude to those observed in endothelial cells fol-
lowing oxidized PAPC treatment [19].
We cannot conclude based on these data that the ef-
fects of this plasmalogen phosphatidylethanolamine are
representative of other ether-linked lipids, including
those ether-linked phosphatidylcholines that were also
identified during our analysis. However, our data suggest
that this lipid may induce changes in endothelial cells in-
dicative of vascular disease, and support further analysis
of the role of ether linked lipids in the vascular
endothelium.
Oxidized phospholipids
The finding that phosphatidylcholine oxidation products
that have been shown in vitro to induce disease related
phenotypic changes in endothelial cells were not elevated
in our obese subjects was unexpected. Because oxidized
phosphatidylcholine products have been found in modi-
fied LDL and atherosclerotic lesions from high fat fed rab-
bits [6] and oxidized LDL has been found in lesions
isolated from human vessels [43], we hypothesized they
would be elevated in morbidly obese subjects compared to
control. Our findings do not discredit the data indicating
detrimental effects of oxidized PAPC on endothelial cells,
however oxidized PAPC products did not drive the separ-
ation between control and obese groups in our model.
Our data support the importance of examining other clas-
ses of lipids and presence of oxidized phospholipids in hu-
man plasma and LDL.
Lipidomic and metabolomic analyses
Each lipidomic and metabolomic analysis is performed
using unique methods and parameters, and generates
unique results contributing to global understanding of
group differences and metabolism. Lipidomics has been
used recently to compare tissues in subjects with the
metabolic syndrome and diabetes, overweight and obese
subjects, and gastric bypass patients among others
[26,44-46]. While lipidomic and metabolomic studies
don’t necessarily address mechanistic questions, infor-
mation obtained using these techniques provides infor-
mation on global differences between groups and often
drives hypothesis development for mechanistic ques-
tions. As such, our analysis revealed a group of ether-
linked lipids that are elevated in morbidly obese humans.
Further, these findings translated to examination of the
pathophysiological roles for this class of lipids, where
PE-(P-18:0/20:4(5Z,8Z,11Z,14Z)) induces cell adhesion
molecule expression in coronary artery endothelial cells.
Limitations in our analysis include a small sample size,
and while all preparation and analysis of samples follow-
ing collection was performed under inert gas, we did not
use an internal antioxidant. The complete class of ether-
linked lipids found in biological samples is very large
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small percentage, therefore its possible that our data are
not generalizable to ether-linked lipids as a class. Re-
gardless, the emergence of the ether-linked lipids of
interest is strongly supported. Data in our lipidomic ana-
lysis show elevated ether-linked lipids in morbidly obese
subjects compared to control. Given the potential patho-
physiological roles of ether-linked lipids, our data sup-
port further investigation of the role this class may play
in obesity associated vascular and metabolic disease.
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